Vanguard Group Inc Graybug Vision, Inc. Transaction History

Vanguard Group Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 10, 2023	BUY	$0.46 - $1.05 $82 - $187	179 Added 0.04%	419,923 $209,000
Q3 2022 Nov 14, 2022	SELL	$0.93 - $1.18 $31,564 - $40,049	-33,940 Reduced 7.48%	419,744 $394,000
Q2 2022 Aug 12, 2022	SELL	$0.76 - $1.25 $1,434 - $2,360	-1,888 Reduced 0.41%	453,684 $494,000
Q1 2022 May 13, 2022	BUY	$1.13 - $1.93 $26,945 - $46,022	23,846 Added 5.52%	455,572 $561,000
Q4 2021 Feb 14, 2022	SELL	$1.74 - $3.6 $1,860 - $3,848	-1,069 Reduced 0.25%	431,726 $790,000
Q3 2021 Nov 12, 2021	BUY	$3.18 - $5.17 $7,657 - $12,449	2,408 Added 0.56%	432,795 $1.44 Million
Q2 2021 Aug 13, 2021	BUY	$3.53 - $6.1 $1.52 Million - $2.63 Million	430,387 New	430,387 $2.34 Million

Ticker GRAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 21,517,700
Market Cap $63.5M
Description
Graybug Vision, Inc., a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the t...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.